Orchid Pharma Jumps 13% as Russia Commercialization Deal Boosts Investor Sentiment

Orchid Pharma attracted strong buying interest on July 8, 2026, with the stock surging nearly 13% in morning trade following the announcement of a licensing and supply agreement with Pharmasyntez JSC. The partnership grants Pharmasyntez exclusive rights to register and commercialize Exblifep (cefepime/enmetazobactam) in Russia, while Orchid Pharma will supply the finished dosage form. Exblifep is a novel antibiotic developed for the treatment of complicated urinary tract infections and hospital-acquired and ventilator-associated bacterial pneumonia (HAP/VAP). Market participants appeared encouraged by the company’s efforts to expand its international presence and unlock new revenue opportunities through strategic commercialization partnerships. The development underscores Orchid Pharma’s focus on strengthening its specialty pharmaceutical portfolio and enhancing its footprint in global regulated markets. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.